SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
155.20    2.40 (1.57%)
Bid:
155.00
Ask:
155.40
Spread: 0.40 (0.258%)
Market Cap: £888.23m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Interim Management Statement

31 Oct 2014 07:00

ELEMENTIS PLC - Interim Management Statement

ELEMENTIS PLC - Interim Management Statement

PR Newswire

London, October 30

Elementis - Interim Management Statement Elementis plc (ELM.L, "Elementis" or the "Group"), the Global SpecialtyChemicals Company, today issues its Interim Management Statement for the threemonths ended 30 September 2014. Commenting on the Group's performance Group Chief Executive, David Dutro, said: "Elementis is pleased to report another resilient performance that furtherdemonstrates our ability to deliver profitable growth in an economicenvironment that continues to be challenging. Our recent investments in newproducts and geographies combined with our strong market positions and customerrelationships mean that we have a broad base of growth opportunities. Togetherwith our ability to generate significant positive cash flow this provides anattractive platform from which to deliver sustainable value to ourshareholders." Specialty Products' sales improved by 6 per cent in both dollars and volumescompared to the same period last year. * In coatings, sales improved by 6 per cent as the business continued to benefit from its broad geographic base and recent investments in growth. North America sales improved by 5 per cent, helped by growing sales from the new decorative additives plant in New Martinsville and defoamer sales from the Hi-Mar acquisition. In Europe, sales were 11 per cent higher, or 8 per cent excluding currency, as the business team there supplemented the subdued underlying growth in Western Europe with sales of new products, as well as additional sales into Eastern Europe and the Middle East. Asia Pacific sales increased by 4 per cent and Latin America sales were similar to the previous quarter as good progress in delivering synergy benefits from the Watercryl acquisition was offset by soft underlying demand due to weak economic activity. * In personal care, sales for the quarter improved by 6 per cent, bringing the sales growth for the first nine months of the year to 16 per cent, as new products and sales into emerging markets continued to drive performance. * Sales to oil and gas drilling improved by 6 per cent as the business returned to more normal operating rates following the slower start to the year. * Operating margin in the quarter was slightly below the same period last year due to the impact of the start-up phase of the recently completed New Martinsville plant, where production activity is building in line with management expectations. Overall pricing and contribution margins across the businesses remained relatively stable. Chromium continued to perform in line with its strategy of delivering stableearnings and cash flow, with sales in the third quarter 2 per cent higher andoperating profit at a similar level to the previous period. The business hascontinued to experience solid demand in its key North American market andrecent improvements in leather tanning activity, which has been relatively softover the last two years, helped increase the percentage of sales to the regionto 68 per cent, compared to 63 per cent in the first six months of the year.Operational efficiencies continue to contribute to the overall stability andperformance of Chromium. The next planned maintenance shutdown is scheduled totake place during the first half of 2015. Strong cash flow continues to be a positive aspect of the Group's performanceand it is anticipated that the end of year balance sheet will show a net cashbalance of at least $40 million. Overall we remain confident in the Group's ability to deliver growth in excessof the underlying economies in which we operate and expect our full yearearnings per share to be in line with market expectations. END Enquiries Elementis plc Tel: +44 (0) 20 7408 9300Brian Taylorson, Finance Director FTI Consulting Tel: +44 (0) 20 3727 1000Deborah ScottMatthew Cole
Date   Source Headline
16th Jan 20251:45 pmRNSHolding(s) in Company
2nd Jan 202510:06 amRNSTotal Voting Rights
24th Dec 20247:00 amRNSDirectorate Change
9th Dec 20245:05 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:06 amRNSTotal Voting Rights
18th Nov 20247:00 amRNSChief Executive Succession
1st Nov 20249:54 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSThird Quarter Trading Update
11th Oct 202411:18 amRNSDirector/PDMR Shareholding
17th Sep 20248:50 amRNSDirector/PDMR Shareholding
2nd Sep 20249:31 amRNSBlock listing Interim Review
23rd Aug 202410:31 amRNSHolding(s) in Company
14th Aug 202410:53 amRNSAdditional Listing
9th Aug 20242:43 pmRNSHolding(s) in Company
2nd Aug 20245:44 pmRNSHolding(s) in Company
1st Aug 20243:10 pmRNSCorrection of dividend record date
1st Aug 20247:00 amRNSHalf-year Report
15th Jul 202410:59 amRNSHolding(s) in Company
30th May 202412:52 pmRNSDirector/PDMR Shareholding
29th May 20241:07 pmRNSDirector Declaration
8th May 202411:08 amRNSDirector/PDMR Shareholding
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.